CO2021001277A2 - Inhibidores de triazol glicolato oxidasa - Google Patents

Inhibidores de triazol glicolato oxidasa

Info

Publication number
CO2021001277A2
CO2021001277A2 CONC2021/0001277A CO2021001277A CO2021001277A2 CO 2021001277 A2 CO2021001277 A2 CO 2021001277A2 CO 2021001277 A CO2021001277 A CO 2021001277A CO 2021001277 A2 CO2021001277 A2 CO 2021001277A2
Authority
CO
Colombia
Prior art keywords
oxidase inhibitors
glycolate oxidase
triazole
useful
pharmaceutically acceptable
Prior art date
Application number
CONC2021/0001277A
Other languages
English (en)
Inventor
Hans Maag
Miguel Xavier Fernandes
Robert Zamboni
Elham Akbariromani
Marc-Andre Beaulieu
Yves Leblanc
Pallavi Thakur
Original Assignee
Orfan Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orfan Biotech Inc filed Critical Orfan Biotech Inc
Publication of CO2021001277A2 publication Critical patent/CO2021001277A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención proporciona ácidos carboxílicos de triazol y compuestos relacionados, y también sales farmacéuticamente aceptables de estos, que son útiles como inhibidores de glicolato oxidasa. También se describen las composiciones farmacéuticas y los métodos para tratar la hiperoxaluria primaria, tipo I (f) y cálculos renales.
CONC2021/0001277A 2018-07-06 2021-02-05 Inhibidores de triazol glicolato oxidasa CO2021001277A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US201962827573P 2019-04-01 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (1)

Publication Number Publication Date
CO2021001277A2 true CO2021001277A2 (es) 2021-04-30

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001277A CO2021001277A2 (es) 2018-07-06 2021-02-05 Inhibidores de triazol glicolato oxidasa

Country Status (14)

Country Link
US (2) US11401246B2 (es)
EP (1) EP3817816A1 (es)
JP (1) JP7348705B2 (es)
KR (1) KR20210041564A (es)
CN (1) CN112399873A (es)
AU (1) AU2019297523A1 (es)
BR (1) BR112021000050A2 (es)
CA (1) CA3104529A1 (es)
CO (1) CO2021001277A2 (es)
IL (1) IL279952A (es)
MX (1) MX2021000051A (es)
PE (1) PE20210859A1 (es)
SG (1) SG11202012930RA (es)
WO (1) WO2020010309A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401246B2 (en) 2018-07-06 2022-08-02 Cantero Therapeutics, Inc. Triazole glycolate oxidase inhibitors
CA3155577A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
JP2023510758A (ja) * 2020-01-08 2023-03-15 カンテロ セラピューティクス インコーポレイティド トリアゾール系グリコール酸オキシダーゼ阻害剤の調製方法
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
WO2023064257A1 (en) * 2021-10-11 2023-04-20 Cantero Therapeutics, Inc. 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
CN103906427B (zh) 2012-10-25 2015-12-02 朝日集团控股株式会社 胶乳的增产方法
US20140213538A1 (en) 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
WO2016148193A1 (ja) 2015-03-19 2016-09-22 興人ライフサイエンス株式会社 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物
WO2017100266A1 (en) 2015-12-07 2017-06-15 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
TWI811282B (zh) 2017-12-29 2023-08-11 美商拜奧馬林製藥公司 用於疾病治療之乙醇酸酯氧化酶抑制劑
AR114065A1 (es) 2017-12-29 2020-07-15 Orfan Biotech Inc Inhibidores de glicolato oxidasa y uso de los mismos
WO2019165159A1 (en) 2018-02-23 2019-08-29 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
US11401246B2 (en) 2018-07-06 2022-08-02 Cantero Therapeutics, Inc. Triazole glycolate oxidase inhibitors
TW202115013A (zh) 2019-06-19 2021-04-16 美商拜奧馬林製藥公司 用於治療疾病之乙醇酸氧化酶(glycolate oxidase)抑制劑

Also Published As

Publication number Publication date
MX2021000051A (es) 2021-03-25
KR20210041564A (ko) 2021-04-15
US20230143491A1 (en) 2023-05-11
BR112021000050A2 (pt) 2021-04-06
EP3817816A1 (en) 2021-05-12
PE20210859A1 (es) 2021-05-18
US11401246B2 (en) 2022-08-02
CA3104529A1 (en) 2020-01-09
IL279952A (en) 2021-03-01
JP7348705B2 (ja) 2023-09-21
JP2021530560A (ja) 2021-11-11
WO2020010309A1 (en) 2020-01-09
AU2019297523A1 (en) 2021-02-25
CN112399873A (zh) 2021-02-23
WO2020010309A9 (en) 2020-01-30
SG11202012930RA (en) 2021-01-28
US20210403439A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
DOP2019000030A (es) Inhibidores de cdk2/4/6
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
UY37656A (es) Compuestos que inhiben la proteína mcl-1
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20190124A (es) Inhibidores de ssao de aminopirimidina
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
EA201792214A1 (ru) Соединения замещенного хиназолина
ECSP18083519A (es) Inhibidores de bromodominios
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CL2020000283A1 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2020003666A (es) Compuestos y composiciones para el tratamiento de trastornos hematologicos.
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CL2021001461A1 (es) Moduladores de trex1
EA202193015A1 (ru) Ингибиторы cdk
CL2019003258A1 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos.